Johan Baeck

455 total citations
14 papers, 289 citations indexed

About

Johan Baeck is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Johan Baeck has authored 14 papers receiving a total of 289 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Johan Baeck's work include Advanced Breast Cancer Therapies (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Cancer Treatment and Pharmacology (4 papers). Johan Baeck is often cited by papers focused on Advanced Breast Cancer Therapies (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Cancer Treatment and Pharmacology (4 papers). Johan Baeck collaborates with scholars based in United States, Canada and France. Johan Baeck's co-authors include John Rediske, Sanela Bilic, Brett Ewald, Jennifer Bendiske, Jyotirmoy Dey, Pamela S. Becker, John C. Byrd, William Bensinger, Edward A. Stadtmauer and Susan O’Brien and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Johan Baeck

14 papers receiving 282 citations

Peers

Johan Baeck
Bérengère Vire United States
Sandeep Potluri United Kingdom
Márk Plander Hungary
Margot Jak Netherlands
Erin Jou United States
Jordina Rovira Spain
Scott D. Lunin United States
Jing Christine Ye United States
Cristiana Di Bello Italy
Zsolt Zoltán Fülöp Romania
Bérengère Vire United States
Johan Baeck
Citations per year, relative to Johan Baeck Johan Baeck (= 1×) peers Bérengère Vire

Countries citing papers authored by Johan Baeck

Since Specialization
Citations

This map shows the geographic impact of Johan Baeck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Johan Baeck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Johan Baeck more than expected).

Fields of papers citing papers by Johan Baeck

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Johan Baeck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Johan Baeck. The network helps show where Johan Baeck may publish in the future.

Co-authorship network of co-authors of Johan Baeck

This figure shows the co-authorship network connecting the top 25 collaborators of Johan Baeck. A scholar is included among the top collaborators of Johan Baeck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Johan Baeck. Johan Baeck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Bryce, Alan H., Daniel D. Karp, Scott T. Tagawa, et al.. (2023). A phase 2 study of immunogenic cell death inducer PT-112 in patients with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 41(6_suppl). TPS292–TPS292. 3 indexed citations
2.
Yim, Christina Y., Hannah L. Johnson, Maureen G. Mancini, et al.. (2023). Abstract C128: PT-112, a novel immunogenic cell death inducer, causes ribosomal biogenesis inhibition and organelle stress in cancer cells. Molecular Cancer Therapeutics. 22(12_Supplement). C128–C128. 5 indexed citations
3.
Bulat, Iurie, Yuriy Ostapenko, Zanete Zvirbule, et al.. (2021). Phase 2 study of PD-1 inhibitor JTX-4014 alone and in combination with vopratelimab, an ICOS agonist, in biomarker-selected subjects with metastatic NSCLC after one prior platinum-containing regimen (SELECT).. Journal of Clinical Oncology. 39(15_suppl). TPS9137–TPS9137. 5 indexed citations
4.
Papadopoulos, Kyriakos P., Nehal J. Lakhani, Timothy A. Yap, et al.. (2021). Phase 1, first-in-human trial of JTX-8064, an anti-LILRB2/ILT4 monoclonal antibody, as monotherapy and in combination with anti-PD-1 in adult patients with advanced solid tumors (INNATE).. Journal of Clinical Oncology. 39(15_suppl). TPS2672–TPS2672. 2 indexed citations
5.
Papadopoulos, Kyriakos P., Nehal J. Lakhani, Gerald S. Falchook, et al.. (2020). Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors. Cancer Immunology Immunotherapy. 70(3). 763–772. 5 indexed citations
6.
Forsythe, Anna, et al.. (2018). Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2– metastatic breast cancer. Breast Cancer Targets and Therapy. Volume 10. 69–78. 12 indexed citations
7.
Forsythe, Anna, et al.. (2018). Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer?. Cancer Management and Research. Volume 10. 1015–1025. 4 indexed citations
8.
9.
Burris, Howard A., Sara M. Tolaney, Lowell L. Hart, et al.. (2018). Maintenance of health-related quality of life in elderly patients treated with ribociclib + letrozole in MONALEESA-2.. Journal of Clinical Oncology. 36(15_suppl). 1041–1041. 2 indexed citations
10.
11.
Fanale, Michelle A., Sarit Assouline, John Kuruvilla, et al.. (2013). Phase IA/II, multicentre, open‐label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non‐Hodgkin or Hodgkin lymphoma. British Journal of Haematology. 164(2). 258–265. 58 indexed citations
12.
Byrd, John C., Thomas J. Kipps, Ian W. Flinn, et al.. (2012). Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leukemia & lymphoma. 53(11). 2136–2142. 90 indexed citations
13.
Bensinger, William, Richard T. Maziarz, Sundar Jagannath, et al.. (2012). A phase 1 study of lucatumumab, a fully human anti‐CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. British Journal of Haematology. 159(1). 58–66. 89 indexed citations
14.
Freedman, Arnold S., John Kuruvilla, Sarit Assouline, et al.. (2010). Clinical Activity of Lucatumumab (HCD122) In Patients (pts) with Relapsed/Refractory Hodgkin or Non-Hodgkin Lymphoma Treated In a Phase Ia/II Clinical Trial (NCT00670592). Blood. 116(21). 284–284. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bérengère Vire Breakdown of academic impact, for papers by Sandeep Potluri Breakdown of academic impact, for papers by Márk Plander Breakdown of academic impact, for papers by Margot Jak Breakdown of academic impact, for papers by Erin Jou Breakdown of academic impact, for papers by Jordina Rovira Breakdown of academic impact, for papers by Scott D. Lunin Breakdown of academic impact, for papers by Jing Christine Ye Breakdown of academic impact, for papers by Cristiana Di Bello Breakdown of academic impact, for papers by Zsolt Zoltán Fülöp
Rankless by CCL
2026